On the Biotechnology Frontier: Personalized Medicine, A Discussion with E.J. Brandreth - In 10 years, personalized treatment will become a significant part of the biotechnology sector. - BioPharm


On the Biotechnology Frontier: Personalized Medicine, A Discussion with E.J. Brandreth
In 10 years, personalized treatment will become a significant part of the biotechnology sector.

BioPharm International
Volume 20, Issue 10

On the analysis end, it is new equipment, like DNA sequencers that have become far more efficient and sophisticated. They can analyze multiple samples simultaneously. In the future, we'll be able to increase what we're doing today, logarithmically with computers, and with equipment using microcapillaries. We can now process a thousand samples in the amount of time that one sample took in the past.

What are some of the manufacturing developments that have led to personalized therapies?

After we receive a biopsy sample, sequence the DNA, and determine the relevant sequence for the patient's antibody, we generate a plasmid that is integrated into a virus specific for insect cells. The use of this viral and insect cell system has been a big breakthrough. We use insect cells—Fall Armyworm (Spodoptera frugiperda) and Cabbage Looper (Trichoplusia ni)—with a baculovirus vector. The virus replicates within the insect cells and they produce antibodies with a glycosylation pattern that we believe is best suited for eliciting the immune response we are seeking. In fact, we can generate and harvest a cell culture in a fraction of the time it would take using mammalian cells.

So, how long will it take you to develop a therapeutic for a cancer patient?

Our proprietary production system allows for manufacturing a patient's FavId and returning it to the patient's physician in eight weeks. Mammalian cell production systems require 4–6 months.

Does the manufacture of patient-specific therapies require unique facilities and regulatory considerations?

Safety is always the number one concern, and with insect cells, there is a slightly lower risk of viral contamination for humans compared with mammalian cells.

One of the biggest measures we can take to ensure safety is segregating patient-specific lots. There are different approaches to this. One is through facility design.

We have already completed the construction of a commercial facility. The biggest regulatory concern is segregating the lots of patients' antibodies. We have a dedicated area for the final production phases of each lot, and will be processing and releasing up to 80 lots per week. In any given day, we could have more than 500 lots at various stages of production in the facility. Those are staggering numbers.

The other measure is establishing a dedicated tracking number and bar code for the biopsy sample when it comes through the door, and then following it all the way to the final vial shipped out to the patient.

Another major consideration is scale. We have essentially the same stages as other typical recombinant protein biotech companies: cell culture, purification, formulation and filling, but at a very small scale. We are only making enough vials for one patient.

How do you scale up?

You have to scale up horizontally, not vertically. We have multiples of small pieces of equipment: dozens of laminar air flow hoods and purification skids.

Do you use disposables?

Our entire process uses disposable technology. There are virtually no cleaning validation issues, to avoid the possibility of cross-contamination. The disposable industry has evolved to the point where lots of equipment is available that is presterilized and single-use, and that eliminates validation concerns for cleaning and sterilizing.

What type of testing will be done?

We sequence the patient's DNA at the beginning of the process, and verify it at the end, to make sure the sequence matches what came in. Otherwise, the testing is fairly typical for protein products.

The benefit of patient-specific therapy is doing everything at small scale. When you get to process validation, you can validate at actual commercial scale. In general, the biotech industry has to use scale-down models to validate the process.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here